Boston Scientific
Boston Scientific Corporation, a leading global medical technology company, is headquartered in the United States. Founded in 1979, the company has established itself as a key player in the medical device industry, focusing on innovative solutions across various therapeutic areas, including cardiovascular, rhythm management, and urology. With a strong presence in North America, Europe, and Asia-Pacific, Boston Scientific is renowned for its advanced products and services, such as minimally invasive devices and cutting-edge imaging technologies. The company’s commitment to innovation is exemplified by its numerous milestones, including the development of the first drug-eluting stent. Recognised for its market leadership, Boston Scientific continues to push the boundaries of medical technology, enhancing patient outcomes and improving quality of life. Its dedication to research and development positions it as a trusted partner in healthcare worldwide.
DitchCarbon Score
How does Boston Scientific's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boston Scientific's score of 65 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boston Scientific's reported carbon emissions
In 2023, Boston Scientific reported total greenhouse gas emissions of approximately 102,521,000 kg CO2e, comprising 82,704,000 kg CO2e from Scope 1 and 19,817,000 kg CO2e from Scope 2. The company has set ambitious climate commitments, aiming for net-zero emissions across its value chain by 2050, using 2019 as the baseline year. For the near term, Boston Scientific targets a reduction of absolute Scope 1 and 2 emissions by 46.2% by 2030. Additionally, it aims to reduce Scope 3 emissions—covering categories such as purchased goods and services, capital goods, and business travel—by 55% per USD value added within the same timeframe. Long-term goals include a 97% reduction in Scope 1 and 2 emissions per USD value added, equating to a 90% absolute reduction by 2050, alongside a similar 97% reduction target for Scope 3 emissions. These targets align with the Science Based Targets initiative (SBTi) and reflect Boston Scientific's commitment to sustainable practices in the healthcare equipment and supplies sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 31,257,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 53,870,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boston Scientific is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
